1) In 15 cases of ischemic heart disease (5 cases of type I of the WHO classification, 6 cases of type III and 4 cases of type IV), pyridinolcarbamate (Anginin) (750 to 2,250mg./day) was given orally for 2 to 6 weeks to determine the effect.
SUMMARY
1) In 15 cases of ischemic heart disease (5 cases of type I of the WHO classification, 6 cases of type III and 4 cases of type IV), pyridinolcarbamate (Anginin) (750 to 2,250mg./day) was given orally for 2 to 6 weeks to determine the effect.
2) In subjective symptoms, a positive effect was obtained in 9 of 11, while 4 of 14 showed a positive effect in ECG findings (cases without symptoms or findings before administration were excluded). In type I (WHO classification) subjective symptoms improved in all of the 5 cases, and ECG findings improved in 3 cases. In type III, on the other hand, subjective symptoms improved in 4 of 6 but ECG findings improved only in 1. No effect was seen in 4 cases of type IV.
3) As side effects, headache and a sensation of chest compression were seen in one case each. No other side effects were seen under the experimental conditions of the present study. Additional Indexing Words : Anti-bradykinin preparations Treatment of angina pectoris WHO classification. YRIDINOLCARBAMATE (Anginin), an anti-bradykinin preparation, developed by Professor Shimamoto and associates,1)-4) has been tried in arteriosclerosis,5) inflammation,7) purpura and many other diseases.6)-9) In the treatment of angina pectoris, attention has been focussed on this preparation as an agent with a mechanism of action entirely different from that of conventional coronary vasodilators. In the present study, we used this preparation in 15 cases of ischemic heart disease to study as carefully as possible the changes in subjective symptoms and ECG changes. The following results were obtained.
MATERIALS AND METHODS
Fifteen patients, 12 hospitalized in our Department and 3 ambulant patients consisting of 11 males and 4 females ranging in age from 30 to 60 years, were selected for study. More pronounced changes were not seen during exercise. After 2 weeks , the resting showed some improvement, simulating the findings before administration . Table II. EGG Changes before Changes after loading were also similar to those before administration. After 4
weeks, the height of T in III, aVF at rest decreased and ST. T changes in V4 was pronounced, but ST changes in V5 and V6 after loading were milder than before administration.
and after Anginin Administration Jap. Heart J. July, 1968 In summary, the resting ECG became aggravated after 1 week, recovered after 2 weeks, and reaggravated after 4 weeks, while the ECG after loading was approximately similar to the tracing before administration, and improved after 4
weeks. The evaluation, in other words, was extremely difficult. 
SIDE EFFECTS
One patient complained of mild headache during the administration of this preparation, while another complained of a sensation of pressure in the chest 30min. after administration. In the former case, no such symptom was noted upon placebo administration, while improvement of the symptom was seen after discontinuation in the latter case. Neither gastrointestinal symptoms nor functional disturbances of the liver were noted under the conditions of the present experiment.
DISCUSSION
The evaluation of the effect of therapeutic remedies for angina pectoris is extremely difficult because of the following reasons.
1) Natural fluctuation of the disease process needs to be taken into consideration.
2) Symptoms and ECG findings may improve as the result of rest alone after hospitalization.
3) Improvement may be seen due to the psychological effect of drugs.
Consequently, a sufficiently long observation period is necessary for the evaluation of effect. For these reasons, the administration of Anginin was started after making the disease picture as constant as possible. ECG at rest or after Master's double exercise test was used for the evaluation of the state of the patient. Cases were divided according to the WHO classification. As the result, some improvement was seen in 9 of 11 cases with positive subjective symptoms among the 15 cases. Both of the 2 cases in which symptoms were unchanged belonged to type III, WHO classification. ECG changes responded most favorably in type I. In type III, improvement was seen in 1 of 5 cases in which ECG changes were satisfactorily traced back to the pre-administration stage. In type IV, no change was seen in any of the 4. From these results, it was found that subjective symptoms seldom disappeared completely but some improvement occurred in many (9 of 11 cases). In the present experiment, placebo was used only in some cases, These results probably represented a somewhat better response to the present preparation than to the placebo. The effect on ECG was frequently difficult to evaluate in detailed comparative studies according to the course of the disease. Improvement was frequently seen in type I but rare in type IV, as was naturally expected from the disease picture. Among the same ischemic heart diseases, several types should be classified for the study.
The above was the study on the clinical effect of Anginin in our Department. The mechanism of action of this preparation is quite unique, so that the combined use with drugs with a different mechanism of action might further facilitate the therapeutic effect in ischemic heart disease.
